MUC1 Predicts Colorectal Cancer Metastasis: A Systematic Review and Meta-Analysis of Case Controlled Studies

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Sep 15

PMID 26367866

Citations 30

Authors

Yunhui Zeng

Qiongwen Zhang

Yujie Zhang

Minxun Lu

Yang Liu

Tianying Zheng

Shijian Feng

Meiqin Hao

Huashan Shi

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the predicting value of MUC1 expression in lymph node and distant metastasis of colorectal cancer (CRC).

Methods: Pubmed/ MEDLINE and EMBASE were searched to identify eligible studies that evaluated the correlation between MUC1 and CRC. A meta-analysis was conducted to evaluate the impact of MUC1 expression on CRC metastasis.

Results: A total of 18 studies (n = 3271) met inclusion criteria and the mean Newcastle-Ottawa Scale (NOS) score was 6.3 with a range from 4 to 8. The pooled OR in the meta-analysis of 15 studies indicated that positive MUC1 expression correlated with more CRC node metastasis (OR = 2.32, 95% CI = 1.63-3.29). The data synthesis of 6 studies suggested that MUC1 expression predicted more possibility of CRC distant metastasis (OR = 2.22, 95% CI = 1.23-4.00). In addition, the combined OR of 7 studies showed that MUC1 expression indicated higher Duke's stage (OR = 3.02, 95% CI = 2.11-4.33). No publication bias was found in the mate-analysis by Begg's test or Egger's test with the exception of the meta-analysis of MUC1 with CRC node metastasis (Begg's test p = 0.729, Egger's test p = 0.000).

Conclusions: Despite of some modest bias, the pooled evidence suggested that MUC1 expression was significantly correlated with CRC metastasis.

Citing Articles

Dual-functional probe for sensitive detection of MCF-7 cells and mendelian randomization analysis of MUC1 association with multiple cancers.

Wu Z, Chen Q, Lin Z, Chen Y, Gan X, He Y Sci Rep. 2025; 15(1):6167.

PMID: 39979505 PMC: 11842835. DOI: 10.1038/s41598-025-90575-2.

Therapeutic Applications of Rosmarinic Acid in Cancer-Chemotherapy-Associated Resistance and Toxicity.

Villegas C, Cortez N, Ogundele A, Burgos V, Pardi P, Cabrera-Pardo J Biomolecules. 2024; 14(7).

PMID: 39062581 PMC: 11274592. DOI: 10.3390/biom14070867.

Markers of Epithelial-Mesenchymal Transition and Mucinous Histology Are Significant Predictors of Disease Severity and Tumor Characteristics in Early-Onset Colorectal Cancer.

Djikic Rom A, Dragicevic S, Jankovic R, Radojevic Skodric S, Sabljak P, Markovic V Diagnostics (Basel). 2024; 14(14).

PMID: 39061649 PMC: 11275501. DOI: 10.3390/diagnostics14141512.

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression.

Tian H, Yu J, Chu X, Guan Q, Liu J, Liu Y Front Oncol. 2024; 14:1389713.

PMID: 38699634 PMC: 11063370. DOI: 10.3389/fonc.2024.1389713.

The Role of Liquid Biopsy in the Diagnosis and Prognosis of WHO Grade 4 Astrocytoma.

Halawa T, Baeesa S, Fadul M, Badahdah A, Enani M, Fathaddin A Cureus. 2023; 15(6):e41221.

PMID: 37525780 PMC: 10387356. DOI: 10.7759/cureus.41221.

References

Mulder W, Stukart M, de Windt E, Wagstaff J, Scheper R, Bloemena E . Mucin-1-related T cell infiltration in colorectal carcinoma. Cancer Immunol Immunother. 1996; 42(6):351-6. PMC: 11037846. DOI: 10.1007/s002620050293. View

Kashiwagi H, Kijima H, Dowaki S, Ohtani Y, Tobita K, TSUKUI M . DF3 expression in human gallbladder carcinoma: significance for lymphatic invasion. Int J Oncol. 2000; 16(3):455-9. DOI: 10.3892/ijo.16.3.455. View

Guo Q, Tang W, Inagaki Y, Midorikawa Y, Kokudo N, Sugawara Y . Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues. World J Gastroenterol. 2006; 12(1):54-9. PMC: 4077483. DOI: 10.3748/wjg.v12.i1.54. View

Kimura T, McKolanis J, Dzubinski L, Islam K, Potter D, Salazar A . MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2012; 6(1):18-26. PMC: 3536916. DOI: 10.1158/1940-6207.CAPR-12-0275. View

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

Beatson R, Taylor-Papadimitriou J, Burchell J . MUC1 immunotherapy. Immunotherapy. 2010; 2(3):305-27. DOI: 10.2217/imt.10.17. View

Karamitopoulou E, Zlobec I, Patsouris E, Peros G, Lugli A . Loss of E-cadherin independently predicts the lymph node status in colorectal cancer. Pathology. 2011; 43(2):133-7. DOI: 10.1097/PAT.0b013e3283425b7f. View

Nakamori S, Ota D, Cleary K, SHIROTANI K, Irimura T . MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology. 1994; 106(2):353-61. DOI: 10.1016/0016-5085(94)90592-4. View

Bitler B, Goverdhan A, Schroeder J . MUC1 regulates nuclear localization and function of the epidermal growth factor receptor. J Cell Sci. 2010; 123(Pt 10):1716-23. PMC: 2864713. DOI: 10.1242/jcs.062661. View

10.

Chaika N, Gebregiworgis T, Lewallen M, Purohit V, Radhakrishnan P, Liu X . MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proc Natl Acad Sci U S A. 2012; 109(34):13787-92. PMC: 3427054. DOI: 10.1073/pnas.1203339109. View

11.

Gendler S . MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia. 2001; 6(3):339-53. DOI: 10.1023/a:1011379725811. View

12.

Winter J, Tang L, Klimstra D, Brennan M, Brody J, Rocha F . A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One. 2012; 7(7):e40157. PMC: 3391218. DOI: 10.1371/journal.pone.0040157. View

13.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

14.

Perez R, Bresciani B, Bresciani C, Proscurshim I, Kiss D, Gama-Rodrigues J . Mucinous colorectal adenocarcinoma: influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis. Int J Colorectal Dis. 2008; 23(8):757-65. DOI: 10.1007/s00384-008-0486-0. View

15.

Hiraga Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G . Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology. 1998; 55(4):307-19. DOI: 10.1159/000011868. View

16.

Besmer D, Curry J, Roy L, Tinder T, Sahraei M, Schettini J . Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. Cancer Res. 2011; 71(13):4432-42. PMC: 3129481. DOI: 10.1158/0008-5472.CAN-10-4439. View

17.

Luttges J, Feyerabend B, Buchelt T, Pacena M, Kloppel G . The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 2002; 26(4):466-71. DOI: 10.1097/00000478-200204000-00008. View

18.

Hayashi T, Takahashi T, Motoya S, Ishida T, Itoh F, Adachi M . MUC1 mucin core protein binds to the domain 1 of ICAM-1. Digestion. 2001; 63 Suppl 1:87-92. DOI: 10.1159/000051917. View

19.

Kovjazin R, Volovitz I, Kundel Y, Rosenbaum E, Medalia G, Horn G . ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors. Vaccine. 2011; 29(29-30):4676-86. DOI: 10.1016/j.vaccine.2011.04.103. View

20.

Kimura T, Tanaka S, Haruma K, Sumii K, Kajiyama G, Shimamoto F . Clinical significance of MUC1 and E-cadherin expression, cellular proliferation, and angiogenesis at the deepest invasive portion of colorectal cancer. Int J Oncol. 1999; 16(1):55-64. DOI: 10.3892/ijo.16.1.55. View